Cempra Inc (NASDAQ:CEMP) To Target Japanese Market With Solithromycin Phase 3 Clinical Trials
Greg Folin
January 9, 2017
Cempra Inc (NASDAQ:CEMP) kicked into the New Year with a bang, by making announcement of its Phase 3 clinical trials of solithromycin by Toyama Chemical
